Fredrik Piehl obtained his MD at Karolinska Institutet (KI) 1993 and a PhD from the Department of Neuroscience, KI 1996. He did a post-doc 1997-99 in experimental neuroimmunology at the Department of Medicine, Karolinska University Hospital and became a board certified specialist in Clinical Neurology 2005. He became professor of clinical neurology at the Department of Clinical Neurosciences, KI 2009, where he heads a research group focusing on neurodegenerative aspects of neuroinflammation, biomarkers and effects of disease modulatory treatments. He served as head of the clinical neuroimmunology section at the Karolinska University Hospital 2008-2017, and is now head of research at the MS clinic at Academic Specialist Center of Stockholm Health Services, the largest in Sweden with approx. 2000 patients. He is on the scientific advisory board of the Swedish Medical Products Agency, the Neurology Therapeutic Guidelines Committee of Stockholm County, and the Drug Therapeutic Committee of the Karolinska University Hospital, and served as chairman of the Swedish MS Society 2013-2015. He has participated in >15 clinical trials in MS and myasthenia gravis, several of which as country coordinating PI. He is PI of the Combat-MS study, a large nationwide comparative effectiveness and safety study in MS funded by Pcori, Washington DC. He has authored or co-authored close to 200 articles, H-index 49.
